Almac is developing the assay to enroll patients for clinical trials used to develop repotrectinib, an investigational tyrosine kinase inhibitor.
The test is intended to identify patients with ROS1, NTRK, and ALK gene fusions for treatment with TP's investigational drug repotrectinib.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
The collaboration will streamline patient sample analysis to determine whether they should be included in clinical trials for molecularly targeted treatment.
The partners plan to develop a computational platform that automates pipelines and processes for biomarker discovery, drug recovery and repositioning, and more.
The deal allows UK-based Almac to develop NGS assays on the Illumina MiSeqDx instrument.
The firms are developing a gene expression RSPO3 CLIA assay to select patients in the clinical development of OncoMed's therapeutic.
NEW YORK (GenomeWeb) — Pharmaceutical companies are jockeying to formulate companion diagnostics strategies that involve a new microarray-based assay developed by Almac Diagnostics, according to the company.
NEW YORK (GenomeWeb) — Almac Diagnostics has developed a microarray-based test that can be used to determine which ovarian cancer patients will have a good prognosis following chemotherapy.
An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.
In Science this week: reduction in bee phylogenetic diversity, and more.
The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.
The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.